All In Biotech

Drug Trial Radar · NCT06725758

A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours

Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

315

Planned (sponsor's estimate)

Start

Oct 26, 2023

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Sponsor type
Industry
First posted
Dec 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours

Conditions

  • Solid Tumours

Interventions

  • ODM-212Drug

    ODM-212 5mg and/or 40mg tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and frequency of treatment emergent adverse events (TEAE)Time frame: From first dose to 1 year after LSLV
  2. Severity of TEAETime frame: From first dose to 1 year after LSLV

Locations

20 sites in 6 countries. Site status is shown where the registry gives one.

  • Valkyrie Clinical Trials

    Los Angeles, California · Recruiting

  • UC Irvine Health

    Orange, California · Recruiting

  • Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Westchester Medical Center

    Valhalla, New York · Recruiting

  • Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Helsinki university Hospital

    Helsinki, Finland · Recruiting

  • Oulu University Hospital

    Oulu, Finland · Recruiting

  • Turku University Hospital

    Turku, Finland · Recruiting

  • Institut Bergonie

    Bordeaux, France · Recruiting

  • Centre Oscar Lambret

    Lille, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Hospital 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Virgen De La Macarena

    Seville, Spain · Recruiting

  • Istituto Oncologico, Ospedale Bellinzona e Valli

    Bellinzona, Canton Ticino, Switzerland · Recruiting

  • Leicester Royal Infirmary

    Leicester, United Kingdom · Recruiting

  • Royal Marsden Hospital, London, UK

    London, United Kingdom · Recruiting

  • Weston Park Hospital

    Sheffield, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.